161 related articles for article (PubMed ID: 30678447)
1. Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells.
Seyhoun I; Hajighasemlou S; Ai J; Hosseinzadeh F; Mirmoghtadaei M; Seyhoun SM; Parseh B; Abdolahi S; Ghazvinian Z; Shadnoush M; Verdi J
Asian Pac J Cancer Prev; 2019 Jan; 20(1):263-267. PubMed ID: 30678447
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy of sorafenib with mesenchymal stem cells as a novel cancer treatment regimen in xenograft models of hepatocellular carcinoma.
Seyhoun I; Hajighasemlou S; Muhammadnejad S; Ai J; Nikbakht M; Alizadeh AA; Hosseinzadeh F; Mirmoghtadaei M; Seyhoun SM; Verdi J
J Cell Physiol; 2019 Jun; 234(6):9495-9503. PubMed ID: 30362607
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells.
Liu J; Liu Y; Meng L; Ji B; Yang D
Int J Med Sci; 2017; 14(6):523-529. PubMed ID: 28638267
[No Abstract] [Full Text] [Related]
4. Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
Morisaki T; Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M
Anticancer Res; 2013 Apr; 33(4):1387-95. PubMed ID: 23564777
[TBL] [Abstract][Full Text] [Related]
5. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
Wang H; Zhang C; Chi H; Meng Z
Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation.
Wang X; Li H; Li D; Bai Y; Zhang Y; Yan X; Li J; Zhao R; Liu J; Liu W; Shi M; Xu C; Yang T; Zhang T
FEBS Open Bio; 2021 Jan; 11(1):133-145. PubMed ID: 33176070
[TBL] [Abstract][Full Text] [Related]
7. Preparation and characterization of parthenolide nanocrystals for enhancing therapeutic effects of sorafenib against advanced hepatocellular carcinoma.
Liang P; Wu H; Zhang Z; Jiang S; Lv H
Int J Pharm; 2020 Jun; 583():119375. PubMed ID: 32344021
[TBL] [Abstract][Full Text] [Related]
8. Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells.
Cai H; Yang Y; Peng F; Liu Y; Fu X; Ji B
Int J Med Sci; 2019; 16(12):1541-1548. PubMed ID: 31839741
[No Abstract] [Full Text] [Related]
9. Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid.
Yurdacan B; Egeli U; Guney Eskiler G; Eryilmaz IE; Cecener G; Tunca B
J Pharm Pharmacol; 2019 Jul; 71(7):1119-1132. PubMed ID: 31025377
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of the microtubule inhibitor MBRI-001 against human hepatocellular carcinoma as monotherapy or in combination with sorafenib.
Deng M; Li L; Zhao J; Yuan S; Li W
Cancer Chemother Pharmacol; 2018 May; 81(5):853-862. PubMed ID: 29532153
[TBL] [Abstract][Full Text] [Related]
11. Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
Dai N; Ye R; He Q; Guo P; Chen H; Zhang Q
Oncol Rep; 2018 Dec; 40(6):3235-3248. PubMed ID: 30272354
[TBL] [Abstract][Full Text] [Related]
12. Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism.
Kim YS; Lee YM; Oh TI; Shin DH; Kim GH; Kan SY; Kang H; Kim JH; Kim BM; Yim WJ; Lim JH
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321984
[TBL] [Abstract][Full Text] [Related]
13. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
[TBL] [Abstract][Full Text] [Related]
15. Sirtuin 1 and 2 inhibitors enhance the inhibitory effect of sorafenib in hepatocellular carcinoma cells.
Ceballos MP; Angel A; Delprato CB; Livore VI; Ferretti AC; Lucci A; Comanzo CG; Alvarez ML; Quiroga AD; Mottino AD; Carrillo MC
Eur J Pharmacol; 2021 Feb; 892():173736. PubMed ID: 33220273
[TBL] [Abstract][Full Text] [Related]
16. The Synergistic Cytotoxic Effect of Laser-Irradiated Gold Nanoparticles and Sorafenib Against the Growth of a Human Hepatocellular Carcinoma Cell Line.
Ebrahim HM; El-Rouby MN; Morsy ME; Said MM; Ezz MK
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3369-3376. PubMed ID: 31759361
[TBL] [Abstract][Full Text] [Related]
17. Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma.
Cheng Y; Luo R; Zheng H; Wang B; Liu Y; Liu D; Chen J; Xu W; Li A; Zhu Y
Oncotarget; 2017 Apr; 8(14):23265-23276. PubMed ID: 28423574
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effect of sorafenib and vitamin K on suppression of hepatocellular carcinoma cell migration and metastasis.
Ha TY; Hwang S; Hong HN; Choi YI; Yoon SY; Won YJ; Song GW; Kim N; Tak E; Ryoo BY
Anticancer Res; 2015 Apr; 35(4):1985-95. PubMed ID: 25862851
[TBL] [Abstract][Full Text] [Related]
19. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
20. Liposomal clodronate combined with Cisplatin or Sorafenib inhibits hepatocellular carcinoma cell proliferation, migration and invasion by suppressing FOXQ1 expression.
Zhou Y; Chen Y; Ma C; Shao B; Zhang F
Cell Mol Biol (Noisy-le-grand); 2020 Apr; 66(1):49-54. PubMed ID: 32359383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
